Medicover Genetics marks 10 years of VERACITY: A decade of innovation, clinical trust, and scientific progress

was among the very first NIPTs available in the international market. Over the past decade, the test was made available in over 60 countries, and it has set new standards in accuracy, reliability, and clinical value. The test is validated for singleton, twin, IVF, and vanishing twin pregnancies, and has consistently delivered robust and industry leading performance data which have been published in peer review journals.

Advancing science to meet clinical needs

As part of our ongoing commitment to scientific excellence and continuous innovation, Medicover Genetics is pleased to announce the launch of an enhanced microdeletion panel, further expanding VERACITY and NIPTs’ clinical capabilities.

Starting in mid-November 2025, both VERACITY and VERAgene NIPTs will include prevalent and clinically significant microdeletion syndromes: , and Cri-du-chat.

In addition, our NIPTs have now been validated from the 9th week of pregnancy, allowing for reliable results earlier in gestation and supporting timely, informed decision-making.

Phase 1 availability: These new enhancements will be initially implemented at Medicover Genetics’ laboratories in Cyprus, before being introduced across additional laboratories within the Medicover Genetics’ network.

Innovation driven by purpose

VERACITY’s proprietary technology is built on targeted-capture enrichment, focusing on clinically meaningful genomic regions while avoiding complex genomic areas. This targeted approach ensures high analytical precision and consistent performance across various pregnancy cases, offering results that are both scientifically robust and clinically relevant.

Our continued enhancement of VERACITY reflects our dedication to addressing evolving clinical needs and market demand, while maintaining the highest standards of quality, accuracy, and scientific integrity.

A decade of collaboration and trust

This milestone is a shared achievement made possible by the trust and collaboration of the medical community, clinical partners, and associates around the world. We sincerely thank all those who have supported VERACITY’s journey over the past ten years and continue to rely on it as a benchmark for excellence in non-invasive prenatal screening.

Looking ahead

As we enter the next decade, Medicover Genetics will continue to invest in research, innovation, and collaboration to make high-quality genetic testing accessible to more people in more countries.

VERACITY. Ten years of trust. Ten years of clinical excellence.